Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Myriad Genetics Inc (MYGN)
Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,367,446
  • Shares Outstanding, K 81,883
  • Annual Sales, $ 678,400 K
  • Annual Income, $ -112,000 K
  • 60-Month Beta 1.78
  • Price/Sales 2.00
  • Price/Cash Flow 87.46
  • Price/Book 1.87
Trade MYGN with:

Options Overview Details

View History
  • Implied Volatility 53.99% ( +1.40%)
  • Historical Volatility 37.26%
  • IV Percentile 28%
  • IV Rank 34.54%
  • IV High 86.62% on 02/28/23
  • IV Low 36.77% on 07/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 186
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 4,211
  • Open Int (30-Day) 3,376

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.16
  • Number of Estimates 6
  • High Estimate -0.13
  • Low Estimate -0.23
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +40.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.14 +9.68%
on 09/08/23
18.34 -9.46%
on 08/31/23
-1.10 (-6.19%)
since 08/25/23
3-Month
15.14 +9.68%
on 09/08/23
24.21 -31.41%
on 06/30/23
-6.16 (-27.04%)
since 06/26/23
52-Week
13.92 +19.29%
on 12/30/22
24.21 -31.41%
on 06/30/23
-1.81 (-9.80%)
since 09/26/22

Most Recent Stories

More News
Advancements in Pancreatic Cancer Treatment: Biotech Innovations and Rising Optimism

USA News Group – According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic cancer increased by 1% from the previous year to 12%. The...

ONCY : 2.13 (unch)
ONC.TO : 2.88 (+0.70%)
SGEN : 216.64 (+0.52%)
MYGN : 16.48 (-1.32%)
ILMN : 128.00 (-2.59%)
BNTX : 101.61 (-1.46%)
Myriad: Q2 Earnings Snapshot

Myriad: Q2 Earnings Snapshot

MYGN : 16.48 (-1.32%)
Stock Index Futures Move Lower as U.S. Debt Ceiling Uncertainty Weighs on Sentiment, PMI Data in Focus

June S&P 500 futures (ESM23) are down -0.14%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.02% this morning as the U.S. debt ceiling impasse kept risk sentiment fragile, while market participants...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
PACW : 7.91 (+1.41%)
NKE : 90.28 (-0.35%)
BAER.Z.IX : 59.040 (+0.44%)
MYGN : 16.48 (-1.32%)
LFCR : 7.91 (-1.25%)
MVST : 1.7650 (+0.28%)
GH : 25.86 (-1.52%)
QTRX : 26.22 (+1.08%)
Exact Sciences Serves Investors Exactly What They Wished For

Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The

EXAS : 66.72 (+1.18%)
LH : 206.87 (-0.74%)
MYGN : 16.48 (-1.32%)
DGX : 124.41 (+0.09%)
Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View

Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.

MYGN : 16.48 (-1.32%)
JNJ : 159.20 (-0.66%)
ISRG : 289.60 (-1.24%)
EW : 70.12 (+0.95%)
Myriad: Q1 Earnings Snapshot

Myriad: Q1 Earnings Snapshot

MYGN : 16.48 (-1.32%)
Will CytomX Therapeutics (CTMX) Report Negative Q1 Earnings? What You Should Know

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CTMX : 1.3100 (+3.97%)
MYGN : 16.48 (-1.32%)
Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing

Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.

MYGN : 16.48 (-1.32%)
PODD : 155.83 (+0.75%)
LNTH : 66.64 (+3.13%)
AVNS : 20.35 (+0.15%)
Myriad Genetics' (MYGN) New Pact to Boost Precision Medicine

Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.

HOLX : 70.02 (-0.16%)
HSIC : 74.30 (+0.75%)
MYGN : 16.48 (-1.32%)
AVNS : 20.35 (+0.15%)
Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access

Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.

ILMN : 128.00 (-2.59%)
HAE : 91.05 (-0.67%)
MYGN : 16.48 (-1.32%)
TRSSF : 1.7200 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made...

See More

Key Turning Points

3rd Resistance Point 17.33
2nd Resistance Point 17.07
1st Resistance Point 16.89
Last Price 16.48
1st Support Level 16.44
2nd Support Level 16.18
3rd Support Level 16.00

See More

52-Week High 24.21
Fibonacci 61.8% 20.28
Fibonacci 50% 19.06
Fibonacci 38.2% 17.85
Last Price 16.48
52-Week Low 13.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar